171 related articles for article (PubMed ID: 22289890)
41. Natural killer cells and anti-tumor immunity.
Nicholson SE; Keating N; Belz GT
Mol Immunol; 2019 Jun; 110():40-47. PubMed ID: 29233542
[TBL] [Abstract][Full Text] [Related]
42. In-vivo imaging of tumor-infiltrating immune cells: implications for cancer immunotherapy.
Zeelen C; Paus C; Draper D; Heskamp S; Signore A; Galli F; Griessinger CM; Aarntzen EH
Q J Nucl Med Mol Imaging; 2018 Mar; 62(1):56-77. PubMed ID: 29191000
[TBL] [Abstract][Full Text] [Related]
43. Label-free and high-throughput bioluminescence detection of uracil-DNA glycosylase in cancer cells through tricyclic cascade signal amplification.
Zhang Y; Li QN; Li CC; Zhang CY
Chem Commun (Camb); 2018 Jun; 54(51):6991-6994. PubMed ID: 29796498
[TBL] [Abstract][Full Text] [Related]
44. Applications of bioluminescence imaging to antiviral research and therapy: multiple luciferase enzymes and quantitation.
Luker KE; Luker GD
Antiviral Res; 2008 Jun; 78(3):179-87. PubMed ID: 18358543
[TBL] [Abstract][Full Text] [Related]
45. Tumor-Targeted Nanomedicine for Immunotherapy.
Cabral H; Kinoh H; Kataoka K
Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
[TBL] [Abstract][Full Text] [Related]
46. A Useful Guide for Analysis of Immune Mediators in Cancer by Fluorochrome (Luminex) Technique.
Faresjö M
Methods Mol Biol; 2020; 2108():3-13. PubMed ID: 31939166
[TBL] [Abstract][Full Text] [Related]
47. Imaging the immune response to monitor tumor immunotherapy.
Wang Q; Ornstein M; Kaufman HL
Expert Rev Vaccines; 2009 Oct; 8(10):1427-37. PubMed ID: 19803763
[TBL] [Abstract][Full Text] [Related]
48. Bioluminescence Methodology for Ion Channel Studies.
Wadsworth PA; Singh AK; Nguyen N; Stephan C; Laezza F
Methods Mol Biol; 2021; 2188():191-228. PubMed ID: 33119853
[TBL] [Abstract][Full Text] [Related]
49. Bioluminescence imaging correlates with tumor serum marker, organ weights, histology, and human DNA levels during treatment of orthotopic tumor xenografts with antibodies.
Poeschinger T; Renner A; Weber T; Scheuer W
Mol Imaging Biol; 2013 Feb; 15(1):28-39. PubMed ID: 22528864
[TBL] [Abstract][Full Text] [Related]
50. Recent achievements of bioluminescence imaging based on firefly luciferin-luciferase system.
Li S; Ruan Z; Zhang H; Xu H
Eur J Med Chem; 2021 Feb; 211():113111. PubMed ID: 33360804
[TBL] [Abstract][Full Text] [Related]
51. Noninvasive visualization of tumor growth in a human colorectal liver metastases xenograft model using bioluminescence in vivo imaging.
Thalheimer A; Korb D; Bönicke L; Wiegering A; Mühling B; Schneider M; Koch S; Riedel SS; Germer CT; Beilhack A; Brändlein S; Otto C
J Surg Res; 2013 Nov; 185(1):143-51. PubMed ID: 23998649
[TBL] [Abstract][Full Text] [Related]
52. Bioluminescence Imaging Applications in Cancer: A Comprehensive Review.
Alsawaftah N; Farooq A; Dhou S; Majdalawieh AF
IEEE Rev Biomed Eng; 2021; 14():307-326. PubMed ID: 32746363
[TBL] [Abstract][Full Text] [Related]
53. Alpha-glycosylceramides enhance the antitumor cytotoxicity of hepatic lymphocytes obtained from cancer patients by activating CD3-CD56+ NK cells in vitro.
Ishihara S; Nieda M; Kitayama J; Osada T; Yabe T; Kikuchi A; Koezuka Y; Porcelli SA; Tadokoro K; Nagawa H; Juji T
J Immunol; 2000 Aug; 165(3):1659-64. PubMed ID: 10903777
[TBL] [Abstract][Full Text] [Related]
54. HTiP: High-Throughput Immunomodulator Phenotypic Screening Platform to Reveal IAP Antagonists as Anti-cancer Immune Enhancers.
Mo X; Tang C; Niu Q; Ma T; Du Y; Fu H
Cell Chem Biol; 2019 Mar; 26(3):331-339.e3. PubMed ID: 30639259
[TBL] [Abstract][Full Text] [Related]
55. High-throughput viability assay using an autonomously bioluminescent cell line with a bacterial Lux reporter.
Class B; Thorne N; Aguisanda F; Southall N; McKew JC; Zheng W
J Lab Autom; 2015 Apr; 20(2):164-74. PubMed ID: 25447977
[TBL] [Abstract][Full Text] [Related]
56. Continuous delivery of D-luciferin by implanted micro-osmotic pumps enables true real-time bioluminescence imaging of luciferase activity in vivo.
Gross S; Abraham U; Prior JL; Herzog ED; Piwnica-Worms D
Mol Imaging; 2007; 6(2):121-30. PubMed ID: 17445506
[TBL] [Abstract][Full Text] [Related]
57. High-throughput method for the analysis of venlafaxine in pharmaceutical formulations and biological fluids, using a tris(2,2'-bipyridyl) ruthenium(II)-peroxydisulphate chemiluminescence system in a two-chip device.
Al Lawati HA; Varma GB; Suliman FE
Luminescence; 2013; 28(1):44-9. PubMed ID: 22259124
[TBL] [Abstract][Full Text] [Related]
58. Antitumor Responses of Invariant Natural Killer T Cells.
Altman JB; Benavides AD; Das R; Bassiri H
J Immunol Res; 2015; 2015():652875. PubMed ID: 26543874
[TBL] [Abstract][Full Text] [Related]
59. Evaluating the effects of immunosuppression by in-vivo bioluminescence imaging after allotransplantation of ovarian grafts.
Lin YH; Yeh YC; Tzeng CR; Shang WJ; Liu JY; Chen CH
Reprod Biomed Online; 2011 Feb; 22(2):220-7. PubMed ID: 21233017
[TBL] [Abstract][Full Text] [Related]
60. Identification of new MRP4 inhibitors from a library of FDA approved drugs using a high-throughput bioluminescence screen.
Cheung L; Yu DM; Neiron Z; Failes TW; Arndt GM; Fletcher JI
Biochem Pharmacol; 2015 Feb; 93(3):380-8. PubMed ID: 25462817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
